211 related articles for article (PubMed ID: 19029465)
1. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study.
Frankel DS; Meigs JB; Massaro JM; Wilson PW; O'Donnell CJ; D'Agostino RB; Tofler GH
Circulation; 2008 Dec; 118(24):2533-9. PubMed ID: 19029465
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance is accompanied by increased von Willebrand factor levels in nondiabetic women: a study of offspring of type 2 diabetic subjects compared to offspring of nondiabetic subjects.
Foss CH; Vestbo E; Frøland A; Ingerslev J; Gjessing HJ; Mogensen CE; Damsgaard EM
J Intern Med; 2002 Aug; 252(2):155-63. PubMed ID: 12190891
[TBL] [Abstract][Full Text] [Related]
3. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men.
Wannamethee SG; Sattar N; Rumley A; Whincup PH; Lennon L; Lowe GD
Diabetes Care; 2008 May; 31(5):995-1000. PubMed ID: 18235054
[TBL] [Abstract][Full Text] [Related]
4. Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register.
Seaman CD; Yabes J; Comer DM; Ragni MV
J Thromb Haemost; 2015 Nov; 13(11):1999-2003. PubMed ID: 26368360
[TBL] [Abstract][Full Text] [Related]
5. ADAMTS13 activity as a novel risk factor for incident type 2 diabetes mellitus: a population-based cohort study.
de Vries PS; van Herpt TT; Ligthart S; Hofman A; Ikram MA; van Hoek M; Sijbrands EJ; Franco OH; de Maat MP; Leebeek FW; Dehghan A
Diabetologia; 2017 Feb; 60(2):280-286. PubMed ID: 27787621
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study.
Rutter MK; Meigs JB; Sullivan LM; D'Agostino RB; Wilson PW
Diabetes; 2005 Nov; 54(11):3252-7. PubMed ID: 16249452
[TBL] [Abstract][Full Text] [Related]
7. The impact of socioeconomic status on cardiovascular risk factors in African-Americans at high risk for type II diabetes. Implications for syndrome X.
Gaillard TR; Schuster DP; Bossetti BM; Green PA; Osei K
Diabetes Care; 1997 May; 20(5):745-52. PubMed ID: 9135936
[TBL] [Abstract][Full Text] [Related]
8. Von Willebrand factor, ADAMTS13 and mortality in dialysis patients.
Ocak G; Roest M; Verhaar MC; Rookmaaker MB; Blankestijn PJ; Bos WJW; Fijnheer R; Péquériaux NC; Dekker FW
BMC Nephrol; 2021 Jun; 22(1):222. PubMed ID: 34134634
[TBL] [Abstract][Full Text] [Related]
9. The effect of multi-factorial intervention on plasma von Willebrand factor, soluble E-selectin and tissue factor in diabetes mellitus: implications for atherosclerotic vascular disease.
Lim HS; Chong AY; Freestone B; Blann AD; Lip GY
Diabet Med; 2005 Mar; 22(3):249-55. PubMed ID: 15717870
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein insulin resistance index, a high-throughput measure of insulin resistance, is associated with incident type II diabetes mellitus in the Prevention of Renal and Vascular End-Stage Disease study.
Flores-Guerrero JL; Connelly MA; Shalaurova I; Gruppen EG; Kieneker LM; Dullaart RPF; Bakker SJL
J Clin Lipidol; 2019; 13(1):129-137.e1. PubMed ID: 30591414
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of retinopathy and a high plasma von Willebrand factor concentration in type 2 diabetic subjects with microalbuminuria.
Jager A; van Hinsbergh VW; Kostense PJ; Emeis JJ; Nijpels G; Dekker JM; Heine RJ; Bouter LM; Stehouwer CD
Nephrol Dial Transplant; 2001 Mar; 16(3):529-36. PubMed ID: 11239027
[TBL] [Abstract][Full Text] [Related]
12. Urine Albumin/Creatinine Ratio Below 30 mg/g is a Predictor of Incident Hypertension and Cardiovascular Mortality.
Sung KC; Ryu S; Lee JY; Lee SH; Cheong E; Hyun YY; Lee KB; Kim H; Byrne CD
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27625343
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of von Willebrand factor in type 2 diabetes patients with and without cardiovascular diseases: A meta-analysis.
Peng X; Wang X; Fan M; Zhao J; Lin L; Liu J
Diabetes Metab Res Rev; 2020 Jan; 36(1):e3193. PubMed ID: 31145835
[TBL] [Abstract][Full Text] [Related]
14. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease.
Meigs JB; Wilson PW; Fox CS; Vasan RS; Nathan DM; Sullivan LM; D'Agostino RB
J Clin Endocrinol Metab; 2006 Aug; 91(8):2906-12. PubMed ID: 16735483
[TBL] [Abstract][Full Text] [Related]
15. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus.
Stehouwer CD; Nauta JJ; Zeldenrust GC; Hackeng WH; Donker AJ; den Ottolander GJ
Lancet; 1992 Aug; 340(8815):319-23. PubMed ID: 1353802
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study.
Bonora E; Kiechl S; Willeit J; Oberhollenzer F; Egger G; Meigs JB; Bonadonna RC; Muggeo M
Diabetes Care; 2007 Feb; 30(2):318-24. PubMed ID: 17259501
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serum von Willebrand factor, but not soluble ICAM and VCAM, for mortality and cardiovascular events is independent of residual renal function in peritoneal dialysis patients.
Dong J; Li YJ; Yang ZK; Xu R
Perit Dial Int; 2014; 34(7):706-13. PubMed ID: 24584618
[TBL] [Abstract][Full Text] [Related]
18. Levels of von Willebrand factor, insulin resistance syndrome, and a common vWF gene polymorphism in non-insulin-dependent (type 2) diabetes mellitus.
Heywood DM; Mansfield MW; Grant PJ
Diabet Med; 1996 Aug; 13(8):720-5. PubMed ID: 8862946
[TBL] [Abstract][Full Text] [Related]
19. Association Between Insulin Resistance and Cardiovascular Disease Risk Varies According to Glucose Tolerance Status: A Nationwide Prospective Cohort Study.
Wang T; Li M; Zeng T; Hu R; Xu Y; Xu M; Zhao Z; Chen Y; Wang S; Lin H; Yu X; Chen G; Su Q; Mu Y; Chen L; Tang X; Yan L; Qin G; Wan Q; Gao Z; Wang G; Shen F; Luo Z; Qin Y; Chen L; Huo Y; Li Q; Ye Z; Zhang Y; Liu C; Wang Y; Wu S; Yang T; Deng H; Zhao J; Shi L; Ning G; Bi Y; Wang W; Lu J
Diabetes Care; 2022 Aug; 45(8):1863-1872. PubMed ID: 35700159
[TBL] [Abstract][Full Text] [Related]
20. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study.
Jager A; van Hinsbergh VW; Kostense PJ; Emeis JJ; Yudkin JS; Nijpels G; Dekker JM; Heine RJ; Bouter LM; Stehouwer CD
Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):3071-8. PubMed ID: 10591689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
